Literature DB >> 10486728

Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy.

M J Schmerr1, A L Jenny, M S Bulgin, J M Miller, A N Hamir, R C Cutlip, K R Goodwin.   

Abstract

Transmissible spongiform encephalopathies in humans and in animals are fatal neuro-degenerative diseases with long incubation times. The putative cause of these diseases is a normal host protein, the prion protein, that becomes altered. This abnormal prion protein is found mostly in the brains of infected individuals in later stages of the disease, but also can be found in lymphoid and other tissues in lower amounts. In order to eradicate this disease in animals, it is important to develop a system that can concentrate the abnormal prion protein and an assay that is very sensitive. The sensitivity that can be achieved with capillary electrophoresis makes it possible to detect the abnormal protein in blood. A peptide from the carboxyl terminal region, amino acid positions 218-232, was labeled with fluorescein during the synthesis of the peptide at the amino terminus. Antibodies that have been produced to this peptide were affinity purified and used in a capillary electrophoresis immunoassay. The amount of fluorescein labeled peptide in the capillary was 50 amol. Blood was obtained from normal sheep and elk, from sheep infected with scrapie and elk infected with chronic wasting disease. Buffy coats and plasma were prepared by a conventional method. After treatment with proteinase K, which destroys the normal protein but not the altered one, the blood fractions were extracted and tested in the capillary electrophoresis immunoassay for the abnormal prion protein. The abnormal prion protein was detected in fractions from blood from infected animals but not from normal animals. This assay makes a pre-clinical assay possible for these diseases and could be adapted to test for the abnormal prion protein in process materials that are used for manufacture of pharmaceuticals and products for human consumption.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486728     DOI: 10.1016/s0021-9673(99)00514-2

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  12 in total

1.  PrP(Sc) is not detected in peripheral blood leukocytes of scrapie-infected sheep: determining the limit of sensitivity by immunohistochemistry.

Authors:  Lynn M Herrmann; Timothy V Baszler; Donald P Knowles; William P Cheevers
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 2.  Variant Creutzfeldt-Jakob disease: a summary of current scientific knowledge in relation to public health.

Authors:  M B Coulthart; N R Cashman
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262

3.  Modification of blood cell PrP epitope exposure during prion disease.

Authors:  Alana M Thackray; Stephen J Ryder; Raymond Bujdoso
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

4.  Concentration of disease-associated prion protein with silicon dioxide.

Authors:  Helen C Rees; Ben C Maddison; Jonathan P Owen; Garry C Whitelam; Kevin C Gough
Journal:  Mol Biotechnol       Date:  2008-12-05       Impact factor: 2.695

5.  Detection of proteinase K resistant proteins in the urine of patients with Creutzfeldt-Jakob and other neurodegenerative diseases.

Authors:  Reza Dabaghian; Inga Zerr; Uta Heinemann; Gianluigi Zanusso
Journal:  Prion       Date:  2008 Oct-Dec       Impact factor: 3.931

Review 6.  Capillary electrophoresis-based immunoassays: principles and quantitative applications.

Authors:  Annette C Moser; David S Hage
Journal:  Electrophoresis       Date:  2008-08       Impact factor: 3.535

Review 7.  Clinical applications of capillary electrophoresis based immunoassays.

Authors:  Annette C Moser; Corey W Willicott; David S Hage
Journal:  Electrophoresis       Date:  2013-11-27       Impact factor: 3.535

8.  Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns.

Authors:  P Brown; R G Will; R Bradley; D M Asher; L Detwiler
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

9.  A short purification process for quantitative isolation of PrPSc from naturally occurring and experimental transmissible spongiform encephalopathies.

Authors:  Magdalini Polymenidou; Susan Verghese-Nikolakaki; Martin Groschup; Melanie J Chaplin; Mick J Stack; Andreas Plaitakis; Theodoros Sklaviadis
Journal:  BMC Infect Dis       Date:  2002-10-08       Impact factor: 3.090

10.  Capillary electrophoresis for the characterization of quantum dots after non-selective or selective bioconjugation with antibodies for immunoassay.

Authors:  Mark Pereira; Edward Pc Lai
Journal:  J Nanobiotechnology       Date:  2008-10-01       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.